CompletedPhase 1NCT03959189

Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1

Studying Myotonic dystrophy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Expansion Therapeutics, Inc.
Principal Investigator
Elliot Ehrich, MD
Chief Medical Officer
Intervention
ERX-963(drug)
Enrollment
12 enrolled
Eligibility
18-65 years · All sexes
Timeline
20192020

Study locations (4)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03959189 on ClinicalTrials.gov

Other trials for Myotonic dystrophy

Additional recruiting or active studies for the same condition.

See all trials for Myotonic dystrophy

← Back to all trials